14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
AGEN vs LCTX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 19, 2026, Agenus Inc. (AGEN) is the stronger overall head-to-head candidate over Lineage Cell Therapeutics, Inc. (LCTX) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AGEN carries a Unified Composite Score of 54.2/100 (HOLD) at $6.14 (3.7x Forward P/E, 38.9% operating margin), whereas LCTX carries 58.9/100 (HOLD) at $0.82 (30.7x Forward P/E, -280.3% operating margin).
Composite vs. Pillar Nuance: While LCTX currently prints a higher short-term Unified Composite Score (58.9/100 HOLD vs. AGEN 54.2/100 HOLD), AGEN captures the overall institutional head-to-head verdict (8–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (38.9% vs. -280.3% operating margin) and revenue trajectory (+4.1% vs. -61.0% YoY).
Technical & Structure Timing Caution: AGEN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.7); meanwhile LCTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Biotechnology value chain with $212.1M market capitalization and -280.3% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ AGEN vs LCTX Key Questions & Quantitative Answers
As of Nov 19, 2026, Agenus Inc. (AGEN) is the stronger overall head-to-head candidate over Lineage Cell Therapeutics, Inc. (LCTX) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AGEN carries a Unified Composite Score of 54.2/100 (HOLD) at $6.14 (3.7x Forward P/E, 38.9% operating margin), whereas LCTX carries 58.9/100 (HOLD) at $0.82 (30.7x Forward P/E, -280.3% operating margin). Composite vs. Pillar Nuance: While LCTX currently prints a higher short-term Unified Composite Score (58.9/100 HOLD vs. AGEN 54.2/100 HOLD), AGEN captures the overall institutional head-to-head verdict (8–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (38.9% vs. -280.3% operating margin) and revenue trajectory (+4.1% vs. -61.0% YoY). Technical & Structure Timing Caution: AGEN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.7); meanwhile LCTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
AGEN leads the Growth & Scale pillar: AGEN posts +4.1% YoY revenue growth and -99.0% YoY earnings growth on $34M TTM revenue (N/A gross margin, 38.9% operating margin), compared with LCTX at -61.0% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (-95.0% gross margin, -280.3% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), AGEN cumulative revenue shifted +175.0% while LCTX shifted +0.0%. In operating R&D and SG&A reinvestment, AGEN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for LCTX.
AGEN screens cheaper on headline valuation multiples. AGEN trades at 3.7x Forward P/E, 27.8x Trailing P/E, 1.44x PEG, and 8.3x EV/Revenue (-103.7% FCF margin), whereas LCTX trades at 30.7x Forward P/E, 30.7x Trailing P/E, 10.64x PEG, and 16.3x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AGEN (-1278.8% ROE) versus LCTX (4.3% ROE) capital efficiency.
In options market volatility and institutional positioning, AGEN carries 167.5% implied volatility (31st %ile, Balanced (25th–60th %ile)), a 0.04x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.58β · 77% Vol realized risk). By comparison, LCTX carries 896.2% implied volatility (100th %ile, Extreme (>80th %ile)), a 1.10x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.36β · 79% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.